Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients
- PMID: 2568886
- PMCID: PMC11038221
- DOI: 10.1007/BF00199210
Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients
Abstract
The effect of mitomycin C administration on the generation of cytotoxic cells, induced by in vitro activation of peripheral blood mononuclear cells (PBM) with interleukin-2, was studied in patients with various carcinomas. The ability of PBM to generate lymphokine-activated killer (LAK) cell activity against Raji cell targets was significantly augmented 5 and 7 days after a single intravenous dose of 12 mg/m2 mitomycin C, when compared to that of PBM obtained before mitomycin C injection. Further, LAK cell activity against autologous tumor cells was also significantly increased after the drug administration. The distribution of lymphocyte subsets exhibited a significant increase in the percentage of CD3+ cells after injection, with the elevation of the CD4/CD8 ratio. Furthermore, the proportion of the CD4+ Leu8+ subpopulation, which identifies inducers of suppression, was significantly reduced. Thus, the decrease in the proportion of suppressor-inducer subsets of PBM might be at least partially, responsible for the augmented generation of LAK cells after mitomycin C administration.
Similar articles
-
Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.Cancer Immunol Immunother. 1993 Sep;37(4):220-6. doi: 10.1007/BF01518514. Cancer Immunol Immunother. 1993. PMID: 8348560 Free PMC article.
-
Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients.Int J Immunopharmacol. 1988;10(1):47-51. doi: 10.1016/0192-0561(88)90149-x. Int J Immunopharmacol. 1988. PMID: 2966774
-
Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.Jpn J Clin Oncol. 1990 Mar;20(1):87-93. Jpn J Clin Oncol. 1990. PMID: 2108272
-
CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.Eur J Immunol. 1989 Jun;19(6):1037-44. doi: 10.1002/eji.1830190613. Eur J Immunol. 1989. PMID: 2502419
-
Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinoma.Cancer Invest. 1994;12(6):588-96. doi: 10.3109/07357909409023043. Cancer Invest. 1994. PMID: 7994593 Clinical Trial.
Cited by
-
Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.Cancer Immunol Immunother. 1992;35(4):246-50. doi: 10.1007/BF01789330. Cancer Immunol Immunother. 1992. PMID: 1511459 Free PMC article.
-
The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer.Jpn J Surg. 1990 May;20(3):365-8. doi: 10.1007/BF02470676. Jpn J Surg. 1990. PMID: 2113592
-
Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer.Cancer Immunol Immunother. 1992;35(3):175-80. doi: 10.1007/BF01756184. Cancer Immunol Immunother. 1992. PMID: 1638553 Free PMC article.
-
Paradoxical enhancement of interleukin-2-mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate.Cancer Immunol Immunother. 1990;32(1):8-12. doi: 10.1007/BF01741718. Cancer Immunol Immunother. 1990. PMID: 2149670 Free PMC article.
-
Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.Cancer Immunol Immunother. 1993 Sep;37(4):220-6. doi: 10.1007/BF01518514. Cancer Immunol Immunother. 1993. PMID: 8348560 Free PMC article.
References
-
- Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res. 1986;46:4213–4216. - PubMed
-
- Berd D, Maguire HC, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res. 1984;44:1375–1380. - PubMed
-
- Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988;48:1671–1675. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials